Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
Adults (≥18 years old) capable of providing informed consent.
For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.
Bulevirtide group: receiving bulevirtide therapy as prescribed.
No Bulevirtide group: not receiving bulevirtide.
Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).
Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.
Pregnancy or lactation.
Inability or unwillingness to provide informed consent.
Research Center of Periodontal-Systemic Interactions
Lead sponsor
University of Medicine and Pharmacy Craiova
Collaborator
Spitalul clinic judetean de urgenta Craiova
Collaborator